Business
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"
PURCHASE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"PURCHASE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s management team will participate in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase and BIO Partnering @ JPM. All events will be held in-person and are scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2023. Details of the events are as follows: Event: Sachs 6th Annual Neuroscience Forum (Panel)Panel Title: Progress in Alzheimer’s and Cognitive Disorders Date: January 8, 2023Time: 9:30 – 10:25 a.m. PTLocation: Marines Memorial Club, San Francisco, CA Event: Sachs 6th Annual Neuroscience Forum (Corporate Presentation)Date: January 8, 2023Time: 11:20 – 11:40 a.m. PT Location: Marines Memorial Club, San Francisco, CA – Room Regimental Event: Biotech Showcase (Panel)Panel Title: CNS Therapeutic Approaches Across the Spectrum Date: January 9, 2023 Time: 8:00 – 9:00 a.m. PT Location: Hilton Union Square, San Francisco, CA – Yosemite A Event: BIO Partnering @ JPM Date: January 9 – 12, 2023 Registration: https://www.bio.org/events/bio-partnering-jpm/registration During all listed conferences, members of the Cognition management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the Company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones. In addition, Cognition will concurrently host one-on-one meetings at the Hotel Fusion located at 140 Ellis Street in San Francisco during JPM Week. If you would like to schedule a meeting, please email Daniel Kontoh-Boateng, [email protected] or Rosalyn Christian, [email protected]. About Cognition Therapeutics, Inc.Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 recept...